GHK-Cu in Nervous System Research: Nerve Cultures, Behaviour, Brain Injury and Ageing-Brain Models

RESEARCH · GHK-CU · NERVOUS SYSTEM MODELS

GHK-Cu in Nervous System Research: Nerve Cultures, Behaviour, Brain Injury and Ageing-Brain Models

PurixLab’s GHK-Cu 50mg is a research vial of the copper(II) complex of glycyl-L-histidyl-L-lysine. Our earlier articles cover a copper-peptide research overview, gene expression and matrix remodelling, copper coordination and speciation, antioxidant and inflammation models and skin permeation and delivery. This article follows a thread that sits well outside skin biology: experiments on nerve cells, peripheral nerve repair, rodent behaviour, brain injury and ageing-brain models. The literature is small, comes from a handful of groups and includes preprints, so the emphasis here is on what each study actually measured. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.

Where the nervous-system hypothesis comes from

A 2012 review recalled that GHK was discovered in 1973 as an activity in human albumin that caused old human liver tissue to synthesise proteins like younger tissue, noted its high affinity for copper ions, and proposed the tripeptide as a possible agent against age-associated neurodegeneration and cognitive decline [1]. A 2017 paper used Broad Institute Connectivity Map data to describe GHK’s effects on the expression of genes relevant to nervous system function, and listed nerve outgrowth, anti-pain and anti-anxiety effects among reported actions [2]. A 2018 review again described GHK as stimulating blood vessel and nerve outgrowth [3]. All three share an author, and the Connectivity Map work infers activity from gene-expression signatures rather than measuring nerve function. The hypothesis therefore needs to be judged by the experimental studies.

Early cultures and a nerve-guide experiment

The oldest experimental record we found is a 1979 culture study. Explants of chick embryo trigeminal ganglion and rat embryonic hippocampus, and dissociated chick cerebral cells, were grown with synthetic Gly-His-Lys in low-serum medium. The tripeptide did not compensate for the nerve-fibre outgrowth seen in full growth medium and did not replace serum, although the growth-area index increased and, in the first days of cell culture, outgrowth of neuronal processes was stimulated [4].

In a rat sciatic nerve lesion model, collagen tubes with covalently bonded cell-adhesive peptides (RGDS, KRDS or GHK) were used as a prosthesis. After 10 days of regeneration the tissues showed enhanced nerve growth factor and neurotrophins NT-3 and NT-4, and morphometry was performed after 30 days [5]. Two features limit interpretation: GHK was immobilised in a scaffold rather than free in solution, and the abstract reports the peptide groups together, so a GHK-specific effect cannot be separated.

Pain and anxiety tests in rodents

A Russian group tested the free tripeptide in behavioural assays. Given intraperitoneally to male rats, it produced an anxiolytic effect in the elevated plus maze that was most pronounced at the lowest amount tested and weakened as the amount increased; replacing L-lysine with D-lysine weakened the effect [6]. In mice, it lengthened the paw-licking latency in the hot-plate test, and the D-lysine analogue was weaker [7]. In a foot-shock model of pain-induced aggression in paired rats, analgesic and anti-aggressive effects were reported, but similar effects followed L-lysine alone at amounts close to its equimolar content in the tripeptide, leading the authors to conclude that the lysine residue plays the key role [8]. That last control is important: it suggests that in these assays an amino acid alone may reproduce the behavioural result. These abstracts describe Gly-His-Lys without copper.

Intracerebral haemorrhage models

In rats given GHK before intracerebral haemorrhage was induced, the peptide improved neurological deficit scores, reduced brain water content and inhibited neuronal apoptosis; in SH-SY5Y cells it prevented hemin-induced apoptosis, an effect linked to downregulation of miR-339-5p and the VEGFA axis [9]. A follow-up by the same group reported reduced brain water content, better neuron survival, lower inflammatory markers and downregulated aquaporin 4 in astrocytes, attributed to the PI3K/AKT pathway and miR-146a-3p [10].

Ageing-brain and Alzheimer’s models

A second cluster comes from a group studying ageing mice. In a short experiment, sleep-deprived aging mice given GHK did not show the acute learning impairment seen in saline-treated controls, and GHK prevented increases in MCP-1 and nitrotyrosine in the hippocampus; the authors state that GHK can pass through the blood-brain barrier [11]. In a preprint, 20-month-old mice given intranasal GHK-Cu for two months showed better spatial memory and learning performance and lower neuroinflammatory and axonal damage markers [12].

In 5xFAD transgenic mice, an Alzheimer’s model, intranasal GHK-Cu given from 4 to 7 months of age delayed cognitive impairment, reduced amyloid plaques and lowered MCP1-mediated inflammation in frontal cortex and hippocampus [13]. A 2026 preprint compared routes in mice aged 20-21 months: intranasal GHK-Cu for 8 weeks improved escape latency in both sexes, whereas intraperitoneal treatment for 5 days gave only a transient improvement in males. Hippocampal RNA sequencing showed divergent programmes, with intranasal treatment suppressing oxidative phosphorylation pathways and intraperitoneal treatment activating them [14].

A separate chemistry paper is often cited alongside these studies. It describes P6, a peptidomimetic built on the GHK motif together with an amyloid-aggregation inhibitor, which sequestered Cu2+ from amyloid beta-copper complexes and protected PC12 cells [15]. P6 is a different molecule from GHK-Cu.

Reading this literature critically

  • Few groups. The reviews share authors [1,2,3], and the ageing-mouse studies share authors with one another [11,13,14].
  • Preprints. Two of the ageing-brain studies were posted as preprints and had not been peer reviewed at the time of their records [12,14].
  • Copper status varies. The behavioural and haemorrhage studies describe GHK, while the ageing and Alzheimer’s work used GHK-Cu [6,9,13]; free GHK and the copper complex should not be treated as interchangeable.
  • Exposure not measured. The abstracts we reviewed do not report brain concentrations of GHK or GHK-Cu, and route alone changed the molecular response [14].
  • No human data. In a PubMed search on 23 October 2026 we found no clinical study of GHK or GHK-Cu with a neurological or cognitive outcome.

GHK-Cu 50mg at PurixLab

GHK-Cu 50mg: a labelled lyophilized research vial with 50mg per vial, C$49 per vial (CAD, before tax), supplied for laboratory research only. It is not a cosmetic; our separate Copper Facial Mask is the finished cosmetic product. Batch documentation is available on request. Product page: purixlab.com/product/ghk-cu-50mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View GHK-Cu 50mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. PubMed 22666519 · PMC3359723 · doi:10.1155/2012/324832
  2. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PubMed 28212278 · PMC5332963 · doi:10.3390/brainsci7020020
  3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed 29986520 · PMC6073405 · doi:10.3390/ijms19071987
  4. Lindner G, Grosse G, Halle W, et al. [The effect of a synthetic tripeptide nervous tissue cultured in vitro]. Z Mikrosk Anat Forsch. 1979;93(5):820-8. PubMed 317547
  5. Ahmed MR, Basha SH, Gopinath D, et al. Initial upregulation of growth factors and inflammatory mediators during nerve regeneration in the presence of cell adhesive peptide-incorporated collagen tubes. J Peripher Nerv Syst. 2005;10(1):17-30. PubMed 15703015 · doi:10.1111/j.1085-9489.2005.10105.x
  6. Bobyntsev II, Chernysheva OI, Dolgintsev ME, et al. Anxiolytic effects of Gly-His-Lys peptide and its analogs. Bull Exp Biol Med. 2015;158(6):726-8. PubMed 25900608 · doi:10.1007/s10517-015-2847-3
  7. Bobyntsev II, Chernysheva OI, Dolgintsev ME, et al. [Effect of Gly-His-Lys peptide and its analogs on pain sensitivity in mice]. Eksp Klin Farmakol. 2015;78(1):13-5. PubMed 25826868
  8. Sever'yanova LА, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bull Exp Biol Med. 2017;164(2):140-143. PubMed 29181666 · doi:10.1007/s10517-017-3943-3
  9. Zhang H, Wang Y, He Z. Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway. Front Neurosci. 2018;12:644. PubMed 30294253 · PMC6158323 · doi:10.3389/fnins.2018.00644
  10. Zhang H, Wang Y, Lian L, et al. Glycine-Histidine-Lysine (GHK) Alleviates Astrocytes Injury of Intracerebral Hemorrhage via the Akt/miR-146a-3p/AQP4 Pathway. Front Neurosci. 2020;14:576389. PubMed 33192260 · PMC7658812 · doi:10.3389/fnins.2020.576389
  11. Rosenfeld M, Nickel K, Ladiges W. GHK peptide prevents sleep-deprived learning impairment in aging mice. Aging Pathobiol Ther. 2023;5(1):33-35. PubMed 37035833 · PMC10081520 · doi:10.31491/apt.2023.03.109
  12. Tucker M, Keely A, Park JY, et al. Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv. 2023:2023.11.16.567423. PubMed 38014118 · PMC10680828 · doi:10.1101/2023.11.16.567423
  13. Tucker M, Liao GY, Keely A, et al. Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Aging Pathobiol Ther. 2024;6(3):102-108. PubMed 40766919 · PMC12323558 · doi:10.31491/apt.2024.09.148
  14. Mazzola J, Rosenfeld M, Tucker M, et al. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Res Sq. 2026:rs.3.rs-9520102. PubMed 42245779 · PMC13232416 · doi:10.21203/rs.3.rs-9520102/v1
  15. Rajasekhar K, Madhu C, Govindaraju T. Natural Tripeptide-Based Inhibitor of Multifaceted Amyloid β Toxicity. ACS Chem Neurosci. 2016;7(9):1300-10. PubMed 27355515 · doi:10.1021/acschemneuro.6b00175

Leave a Comment

Your email address will not be published. Required fields are marked *